{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:58:18Z","timestamp":1789988298090,"version":"4.0.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":3662,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1038\/modpathol.2012.178","type":"journal-article","created":{"date-parts":[[2012,11,16]],"date-time":"2012-11-16T07:41:14Z","timestamp":1353051674000},"page":"S42-S56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"S1","title":["Aggressive B-cell lymphomas: how many categories do we need?"],"prefix":"10.1016","volume":"26","author":[{"given":"Jonathan W","family":"Said","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2012.178_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/PAP.0b013e3181a9d5d2","article-title":"Diffuse aggressive B-cell lymphomas","volume":"16","author":"Said","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"10.1038\/modpathol.2012.178_bib2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2012.178_bib3","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1200\/JCO.2010.28.6674","article-title":"Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma","volume":"28","author":"Drake","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.178_bib4","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1158\/1078-0432.CCR-11-0224","article-title":"MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"17","author":"Alencar","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2012.178_bib5","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.178_bib6","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1182\/blood-2011-03-344374","article-title":"PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma","volume":"118","author":"Gomez-Abad","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib7","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/path.2807","article-title":"The molecular background of aggressive B cell lymphomas as a basis for targeted therapy","volume":"223","author":"de Jong","year":"2011","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2012.178_bib9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1365-2141.2011.09024.x","article-title":"Risk factors and treatment of childhood and adolescent Burkitt lymphoma\/leukaemia","volume":"156","author":"Miles","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2012.178_bib10","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Gutierrez-Garcia","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00129039-200309000-00001","article-title":"Transformation to aggressive B-cell lymphoma: morphology, immunophenotype, and molecular characteristics","volume":"11","author":"Said","year":"2003","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/modpathol.2012.178_bib12","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1200\/JCO.2010.32.7577","article-title":"Transformation of indolent B-cell lymphomas","volume":"29","author":"Montoto","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.178_bib13","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood-2010-12-323238","article-title":"Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma","volume":"117","author":"Dojcinov","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/PAS.0b013e318185d231","article-title":"CD3-positive large B-cell lymphoma","volume":"33","author":"Wang","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2012.178_bib15","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/PAS.0b013e3181db83af","article-title":"Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation","volume":"34","author":"Ruzinova","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2012.178_bib16","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, Doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Supplement 2","key":"10.1038\/modpathol.2012.178_bib17","first-page":"370A","article-title":"Co-expression of MYC and BCL2 protein in R-CHOP treated de novo diffuse large B-cell lymphoma predits poor outcome","volume":"25","author":"Slack","year":"2012","journal-title":"Modern Pathol"},{"key":"10.1038\/modpathol.2012.178_bib18","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.humpath.2012.03.021","article-title":"CD5(\u2212) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case","volume":"43","author":"Izquierdo","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1038\/modpathol.2012.178_bib19","doi-asserted-by":"crossref","unstructured":"Hsiao SC, Cortada IR, Colomo L, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma. Histopathology e-pub ahead of print 29 May 2012.","DOI":"10.1111\/j.1365-2559.2012.04260.x"},{"key":"10.1038\/modpathol.2012.178_bib20","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.humpath.2010.11.015","article-title":"CD5(\u2212) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case","volume":"42","author":"Lucioni","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1038\/modpathol.2012.178_bib21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/10428194.2010.540361","article-title":"Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus","volume":"52","author":"Vela-Chavez","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1038\/modpathol.2012.178_bib22","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":"Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"117","author":"Salles","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/hon.953","article-title":"Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome","volume":"29","author":"Chigrinova","year":"2011","journal-title":"Hematol Oncol"},{"key":"10.1038\/modpathol.2012.178_bib24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","article-title":"Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial","volume":"11","author":"Zinzani","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1038\/modpathol.2012.178_bib25","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2011-03-345272","article-title":"Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment","volume":"118","author":"Alizadeh","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1309\/AJCPJX4BJV9NLQHY","article-title":"The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"135","author":"Meyer","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2012.178_bib27","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib28","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMra0807082","article-title":"Aggressive lymphomas","volume":"362","author":"Lenz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2012.178_bib29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.178_bib30","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3324\/haematol.2011.050617","article-title":"The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age","volume":"96","author":"Mareschal","year":"2011","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2012.178_bib31","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3324\/haematol.2011.057240","article-title":"Classification of diffuse large B-cell lymphoma by immunohistochemistry demonstrates that elderly patients are more common in the non-GC subgroup and younger patients in the GC subgroup","volume":"97","author":"Thunberg","year":"2012","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2012.178_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/path.2864","article-title":"The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL)","volume":"224","author":"Bavi","year":"2011","journal-title":"J Pathol"},{"key":"10.1038\/modpathol.2012.178_bib33","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/leu.2011.378","article-title":"BCL2 mutations in diffuse large B-cell lymphoma","volume":"26","author":"Schuetz","year":"2012","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2012.178_bib34","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.178_bib35","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2012-01-406033","article-title":"MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation","volume":"119","author":"Cuccuini","year":"2012","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome","volume":"25","author":"Li","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2012.178_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib38","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2012.178_bib39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JCO.2007.13.0690","article-title":"LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab","volume":"26","author":"Natkunam","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.178_bib40","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3324\/haematol.2011.056531","article-title":"A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype","volume":"97","author":"Wilson","year":"2012","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2012.178_bib41","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2012.178_bib42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.leukres.2011.12.012","article-title":"The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"36","author":"Castillo","year":"2012","journal-title":"Leuk Res"},{"key":"10.1038\/modpathol.2012.178_bib43","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","article-title":"Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy","volume":"21","author":"Pels","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.178_bib44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2011-03-321349","article-title":"How I treat primary CNS lymphoma","volume":"118","author":"Ferreri","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib45","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2010-07-297861","article-title":"Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma","volume":"117","author":"Sung","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib46","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/blood-2007-10-119099","article-title":"Pathway analysis of primary central nervous system lymphoma","volume":"111","author":"Tun","year":"2008","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2008-04-149005","article-title":"Primary lymphoma of the central nervous system: just DLBCL or not?","volume":"113","author":"Montesinos-Rongen","year":"2009","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1600-0625.2010.01226.x","article-title":"Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas","volume":"20","author":"Kaune","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1038\/modpathol.2012.178_bib49","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/modpathol.2011.62","article-title":"Geographic variation in the prevalence of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a comparative analysis of a Mexican and a German population","volume":"24","author":"Hofscheier","year":"2011","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2012.178_bib50","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/modpathol.2012.52","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation","volume":"25","author":"Montes-Moreno","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2012.178_bib51","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/PAP.0b013e318229bf08","article-title":"Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly","volume":"18","author":"Adam","year":"2011","journal-title":"Adv Anat Pathol"},{"key":"10.1038\/modpathol.2012.178_bib52","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1309\/AJCPOEOXRYIXQZ0F","article-title":"Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics","volume":"135","author":"Qing","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2012.178_bib53","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3324\/haematol.2009.016113","article-title":"Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype","volume":"95","author":"Montes-Moreno","year":"2010","journal-title":"Haematologica"},{"key":"10.1038\/modpathol.2012.178_bib54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.oraloncology.2011.06.506","article-title":"Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas","volume":"47","author":"Boy","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1038\/modpathol.2012.178_bib55","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1309\/AJCPFUR1BK0UODTS","article-title":"Plasmablastic lymphomas with MYC\/IgH rearrangement: report of three cases and review of the literature","volume":"132","author":"Bogusz","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2012.178_bib56","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":"IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas","volume":"34","author":"Valera","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/modpathol.2012.178_bib57","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1309\/AJCPJH6KEUSECQLU","article-title":"Oral and extraoral plasmablastic lymphoma: similarities and differences in clinicopathologic characteristics","volume":"134","author":"Hansra","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2012.178_bib58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1309\/AJCPV1I2QWKZKNJH","article-title":"Plasmablastic lymphoma and related disorders","volume":"136","author":"Hsi","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2012.178_bib59","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1309\/27H8XJH31F3GUNAT","article-title":"Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV","volume":"128","author":"Chang","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2012.178_bib60","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2141.2011.08877.x","article-title":"Burkitt lymphoma in adults","volume":"156","author":"Linch","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1038\/modpathol.2012.178_bib61","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1182\/blood-2010-09-306407","article-title":"AIDS-related BL and CD4 count: a clue?","volume":"116","author":"Smith","year":"2010","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib62","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/leu.2011.156","article-title":"The different epidemiologic subtypes of Burkitt lymphoma share a homogenous micro RNA profile distinct from diffuse large B-cell lymphoma","volume":"25","author":"Lenze","year":"2011","journal-title":"Leukemia"},{"key":"10.1038\/modpathol.2012.178_bib63","series-title":"WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1038\/modpathol.2012.178_bib64","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2012.178_bib65","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2012.178_bib66","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMe068075","article-title":"Burkitt's lymphoma\u2014the message from microarrays","volume":"354","author":"Harris","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2012.178_bib67","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib68","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1309\/AJCP7YLDTJPLCE5F","article-title":"\u2018Double-Hit\u2019 mature B-cell lymphomas show a common immunophenotype by flow cytometry that includes decreased CD20 expression","volume":"134","author":"Wu","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"10.1038\/modpathol.2012.178_bib69","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.humpath.2009.10.027","article-title":"B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology","volume":"41","author":"Carbone","year":"2010","journal-title":"Hum Pathol"},{"issue":"Supplement 2","key":"10.1038\/modpathol.2012.178_bib70","first-page":"361A","article-title":"High-grade B-cell lymphoma with featues intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (grey zone lymphoma): A clinicopathologic analysis of 39 cases","volume":"25","author":"Perry","year":"2012","journal-title":"Modern Pathol"},{"key":"10.1038\/modpathol.2012.178_bib71","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/cncr.26433","article-title":"Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma","volume":"118","author":"Lin","year":"2012","journal-title":"Cancer"},{"key":"10.1038\/modpathol.2012.178_bib72","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1038\/modpathol.2012.178_bib73","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2010.32.8385","article-title":"The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective","volume":"29","author":"Salaverria","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.178_bib74","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2010.33.3252","article-title":"Pathogenesis of non-Hodgkin's lymphoma","volume":"29","author":"Nogai","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2012.178_bib75","doi-asserted-by":"crossref","unstructured":"Janakiram M, Thirukonda VK, Sullivan M, Petrich AM . Emerging therapeutic targets in diffuse large B-cell lymphoma. Curr Treat Options Oncol e-pub ahead of print 2 February 2012.","DOI":"10.1007\/s11864-011-0178-9"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol2012178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2012178","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222029970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222029970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2012178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:06:33Z","timestamp":1760231193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222029970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":75,"alternative-id":["S0893395222029970"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2012.178","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aggressive B-cell lymphomas: how many categories do we need?","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2012.178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}